Journal of Clinical Laboratory Analysis · 2006 · 12 citations · 14 references
Life SciencesGeneticsOncologyGenitourinary OncologyImmunogeneticsMedical GeneticsCytokine BiologyCytokine Gene PolymorphismGenitourinary Cancer EpidemiologyInterleukin Gene VariantsProstate CancerReceptor PolymorphismsCancer Risk AssociationControl Group DesignCytokine Receptor PolymorphismsGenetic Susceptibility To Prostate CancerImmune Gene PolymorphismInterleukin Gene VariationInterleukin-2 Gene VariantsMatched Control Group
Cytokines are reported to be associated with the formation of prostate cancer. Our aim was to investigate whether C/T polymorphisms of the interleukin-2 (IL-2) gene and IL-2 receptor beta (IL-2RB) gene are associated with prostate cancer. We compared the frequency of the polymorphisms of the IL-2 gene and the IL-2RB gene between 96 patients with prostate cancer and 105 healthy male volunteers from the same area (age >60 years). They were followed for at least 5 years. There was a significant difference in distribution of the genotype of the IL-2 gene polymorphism between the prostate cancer group and the control group (P = 0.017). The distribution of the TT homozygote of the IL-2 gene was significantly higher in the cancer group (32.3%) than in the control group (16.2%). However, no significant statistical difference was found between the polymorphism of the IL-2 gene and prostate cancer in survival analysis during a 5-year follow up period (log rank test; P = 0.19). There was no significant difference in the distribution of the genotype of the IL-2RB gene polymorphism between controls and cancer patients (P = 0.388). This study suggests that the IL-2 gene may be associated with susceptibility to prostate cancer in the Taiwan population.
14
Benjamin Sadlack, Jürgen Löhler, Hubert Schorle et al. · European Journal of Immunology · 1995 · 423 citations
Life Sciences, Immunology, Pathology +17
EAU Guidelines on Prostate Cancer
Gunnar Aus, C.C. Abbou, Dalibor Pacík et al. · European Urology · 2001 · 120 citations
Interleukin 2 Gene Therapy for Prostate Cancer: Phase I Clinical Trial and Basic Biology
Arie S. Belldegrun, Cho-Lea Tso, Amnon Zisman et al. · Human Gene Therapy · 2001 · 99 citations
Medicine, Oncology, Pharmacology +15
Immunologic approaches to the treatment of prostate cancer.
David T. Harris, Gary R. Matyas, Leonard G. Gomella et al. · PubMed · 1999 · 83 citations
Medicine, Immunology, Oncology +12
The Difficult Stone Case: Definition and Management
X. Martin, David A. Tolley, Michele Gallucci et al. · European Urology · 2001 · 70 citations